EU-OPENSCREEN-DRIVE (grant agreement No.823893) offers trans-national access to target-based and phenotype-based workflows, proteomics and related advanced mass spectrometry-based technologies, with a…
Compound repurposing is an important strategy for the identification of effective treatment options against SARS-CoV-2 infection and COVID-19 disease.The EU-OPENSCREEN high capacity screening partner…
If you are interested in 3D in vitro models and drug discovery do not miss our recent publication “Academic collaborative models fostering the translation of physiological in vitro systems from basic…
It is our pleasure to welcome you to the European Chemical Biology Symposium (ECBS) 2021, May 26-28, which is jointly organised by EU-OPENSCREEN and the EuChemS Division of Chemistry for Life Sciences…
With more than 170 participants from the ERIC/RI communities, ESFRI, European Commission and more, the ERIC Forum 2021 was a great opportunity for timely and fruitful discussions on high-level science…
EU-OPENSCREEN Director General, Wolfgang Fecke, will continue to support the work of the Executive Board for the life sciences cluster, Franciska de Jong, Executive Director, CLARIN ERIC, for the…
The European Commission has launched a manifesto to maximise the accessibility of research results in the fight against COVID-19. The manifesto provides guiding principles for beneficiaries of EU…
We are proud to welcome the Translational Medicinal and Biological Chemistry Laboratory headed by Prof. Ana Martinez, at the Margarita Salas Center for Biological Research (Centro de Investigaciones…
In FBDD low-molecular-weight fragments (<250 Da) are screened using structural biology and biophysical techniques to identify hits, which commonly have lower binding affinities (in the range of…
